20/20 Biolabs, Inc. (AIDX) Key Metrics
AIDX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $3.3M
- Enterprise value
- $1.5M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 1.6
- Price / book
- 3.4
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −0.42
AIDX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsAIDX returns How much profit the business earns on the capital it uses.
Return on invested capital+251.1 pts
−2.0%
2025 · hover or tap a bar for each year
20162025
Return on assets+14.8 pts
−96.5%
2025 · hover or tap a bar for each year
20162025
Asset turnover+50.3%
0.53
2025 · hover or tap a bar for each year
20162025
AIDX per-share figures Results divided by the shares outstanding at year-end.
Revenue per share−10.5%
$0.33
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$0.60
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$306.83
2025 · hover or tap a bar for each year
20162025
Book value per share
−$0.00
2025 · hover or tap a bar for each year
20162025
Shares outstanding+30.3%
6.3M
2025 · hover or tap a bar for each year
20162025
AIDX financial health Debt, liquidity and how easily interest is covered.
Net debt+$258.3M
$258.0M
2025 · hover or tap a bar for each year
20162025
Current ratio−60.2%
0.60
2025 · hover or tap a bar for each year
20162025
Interest coverage
-21.3
2025 · hover or tap a bar for each year
20162025
Debt / assets+73,994.1%
310.35
2025 · hover or tap a bar for each year
20162025
AIDX efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+17,834 days
17,855 days
2025 · hover or tap a bar for each year
20162025
Days of inventory+14,715 days
14,729 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding+109,982 days
110,078 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle−77,433 days
-77,494 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue0.0 pts
0.0%
2025 · hover or tap a bar for each year
20162025
AIDX returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
AIDX debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
AIDX key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Per share | ||||||||||
| Revenue per share | $0.33 | $0.37 | $0.30 | $1.17 | $1.02 | $0.49 | $0.06 | $0.06 | $0.07 | $0.09 |
| Earnings per share | −$0.60 | −$1.16 | −$1.34 | $0.23 | $0.22 | −$0.43 | −$0.51 | −$0.31 | −$0.27 | −$0.48 |
| Operating cash flow per share | −$306.83 | −$0.54 | −$0.97 | $0.61 | −$0.11 | −$0.43 | −$0.45 | −$0.28 | −$0.23 | −$0.41 |
| Free cash flow per share | −$306.83 | −$0.54 | −$0.97 | $0.58 | −$0.14 | −$0.47 | −$0.45 | −$0.29 | −$0.23 | −$0.41 |
| Cash per share | $163.98 | $0.37 | $0.86 | $0.93 | $0.35 | $0.73 | $0.48 | $0.69 | $0.22 | $0.21 |
| Book value per share | −$0.00 | $0.32 | $0.90 | $0.99 | $0.73 | $0.72 | $0.45 | $0.70 | $0.10 | $0.17 |
| Tangible book value per share | −$32.33 | $0.22 | $0.79 | $0.91 | $0.67 | $0.59 | $0.32 | $0.56 | $0.06 | $0.13 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.03 | $0.02 | $0.04 | $0.00 | $0.01 | $0.00 | $0.00 |
| Debt per share | $205.23 | $0.32 | $0.43 | $0.25 | $0.25 | $0.03 | — | — | — | — |
| Shares outstanding | 6.3M | 4.8M | 4.8M | 9.5M | 9.5M | 4.7M | 4.7M | 4.7M | 4.6M | 4.6M |
| Change in shares outstanding | +30.3% | +0.7% | −49.7% | +0.3% | +100.2% | +0.0% | +0.3% | +1.7% | +0.7% | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | −190.7% | −93.6% | 26.9% | 40.3% | −73.0% | −89.3% | −78.2% | −203.8% | −284.1% |
| Return on invested capital (ROIC) | −2.0% | −253.1% | −191.4% | 29.9% | 51.5% | — | — | — | — | — |
| Return on assets (ROA) | −96.5% | −111.2% | −68.8% | 19.4% | 27.7% | −51.8% | −67.1% | −52.9% | −91.3% | −165.5% |
| Return on tangible assets | — | −178.3% | −109.4% | 19.0% | 21.4% | −49.8% | −98.3% | −42.2% | −103.5% | −190.8% |
| Free cash flow margin | — | −148.3% | −325.6% | 50.1% | −13.5% | −95.3% | −737.1% | −497.6% | −338.7% | −443.7% |
| Income quality (OCF / net income) | — | — | — | 2.65 | −0.52 | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $1.28B | $1.5M | $2.1M | $2.4M | $2.4M | $144,107 | — | — | — | — |
| Cash & short-term investments | $1.03B | $1.8M | $4.1M | $8.8M | $3.4M | $3.5M | $2.3M | $3.3M | $1.0M | $982,225 |
| Net debt | $258.0M | −$270,611 | −$2.0M | −$6.4M | −$1.0M | −$3.3M | −$2.3M | −$3.3M | −$1.0M | −$982,225 |
| Debt / equity | — | 0.99 | 0.48 | 0.26 | 0.34 | 0.04 | — | — | — | — |
| Debt / assets | 310.35 | 0.42 | 0.33 | 0.20 | 0.23 | 0.03 | — | — | — | — |
| Net debt / EBITDA | — | — | — | −3.25 | −0.48 | — | — | — | — | — |
| Current ratio | 0.60 | 1.50 | 4.25 | 5.97 | 3.52 | 3.07 | 2.46 | 4.06 | 1.18 | 1.94 |
| Quick ratio | −46.59 | 1.47 | 4.19 | 5.92 | 3.41 | 2.98 | 2.42 | 4.03 | 1.14 | 1.86 |
| Interest coverage | -21.3 | -447.7 | -227.9 | 107.0 | 150.2 | — | — | — | — | -235.5 |
| Working capital | −$992,008 | $679,147 | $3.3M | $8.1M | $5.7M | $2.6M | $1.4M | $2.5M | $177,563 | $525,927 |
| Invested capital | $258.0M | $1.3M | $2.3M | $3.0M | $5.9M | $65,134 | −$134,498 | $11,173 | −$583,899 | −$197,864 |
| Tangible asset value | −$202.3M | $1.0M | $3.8M | $8.6M | $6.3M | $2.8M | $1.5M | $2.6M | $255,625 | $605,844 |
| Net current asset value | −$2.7M | −$44,701 | $2.2M | $6.9M | $4.6M | $2.5M | $1.4M | $2.5M | $176,063 | $524,427 |
| Graham number | — | — | — | $2.26 | $1.89 | — | — | — | — | — |
| Graham net-net per share | $196.58 | −$0.04 | $0.44 | $0.69 | $0.34 | $0.50 | $0.29 | $0.53 | $0.03 | $0.10 |
| Capital allocation | ||||||||||
| Capex / revenue | 0.0% | 0.0% | 0.7% | 2.4% | 2.4% | 7.9% | 0.8% | 23.1% | 0.0% | 0.0% |
| Capex / operating cash flow | — | — | — | 4.5% | — | — | — | — | — | — |
| Capex / depreciation | 0.00 | 0.00 | 0.06 | 0.91 | 1.84 | 2.83 | 0.05 | 2.08 | 0.00 | 0.00 |
| Stock-based compensation / revenue | 25.2% | 124.2% | 91.6% | — | — | — | — | — | — | — |
| R&D / revenue | 29.0% | 72.0% | 98.9% | 1.1% | 2.0% | 14.5% | 67.7% | 84.6% | 85.3% | 99.4% |
| SG&A / revenue | 163.5% | 271.6% | 355.4% | — | — | — | — | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | 17,855.2 | 21.3 | 106.8 | 82.2 | 83.8 | 18.6 | 30.4 | 45.2 | 56.7 | 37.8 |
| Days of inventory on hand | 14,728.8 | 14.1 | 20.5 | 10.3 | 13.0 | 17.4 | 42.7 | 53.8 | 81.8 | 62.5 |
| Days payables outstanding | 110,077.9 | 96.0 | 114.4 | 39.9 | 48.3 | 107.2 | 491.2 | 488.2 | 389.4 | 191.5 |
| Cash conversion cycle (days) | -77,493.9 | -60.6 | 12.9 | 52.5 | 48.5 | -71.2 | -418.1 | -389.3 | -250.9 | -91.2 |
| Receivables turnover | 0.02 | 17.17 | 3.42 | 4.44 | 4.35 | 19.62 | 12.02 | 8.08 | 6.44 | 9.66 |
| Payables turnover | 0.00 | 3.80 | 3.19 | 9.14 | 7.55 | 3.40 | 0.74 | 0.75 | 0.94 | 1.91 |
| Inventory turnover | 0.02 | 25.82 | 17.80 | 35.58 | 28.15 | 20.92 | 8.54 | 6.79 | 4.46 | 5.84 |
| Asset turnover | 0.53 | 0.35 | 0.15 | 0.98 | 1.29 | 0.60 | 0.08 | 0.10 | 0.23 | 0.32 |
| Average receivables | $100.0M | $102,053 | $416,879 | $2.5M | $2.2M | $118,784 | $23,993 | $34,297 | $48,662 | $44,217 |
| Average payables | $434.5M | $366,291 | $412,280 | $649,276 | $652,662 | $426,889 | $355,195 | $291,054 | $194,438 | $134,437 |
| Average inventory | $58.1M | $53,916 | $73,871 | $166,866 | $175,050 | $69,459 | $30,888 | $32,045 | $40,828 | $43,864 |
| Intangibles / total assets | 4,888.7% | 13.8% | 8.3% | 6.0% | 5.7% | 13.3% | 21.1% | 15.6% | 14.1% | 13.3% |
Computed from AIDX's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
AIDX valuation and financial ratios
20/20 Biolabs earned a return on invested capital of −2.0% in fiscal 2025. It ended the year with $1.3 billion of debt and $1.0 billion in cash and short-term investments, net debt of $258.0 million. The share count rose 36.0% from 4.6M to 6.3M over 9 years.
See the AIDX income statement, the AIDX chart for price history, or the AIDX stock overview for the latest quote and news.
AIDX key metrics FAQ
What is 20/20 Biolabs's ROIC?
20/20 Biolabs's return on invested capital was −2.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does 20/20 Biolabs have?
20/20 Biolabs had total debt of $1.3 billion at the end of fiscal 2025.
What is 20/20 Biolabs's current ratio?
20/20 Biolabs's current ratio was 0.60 at the end of fiscal 2025: current assets were 0.60 times current liabilities.